While voluntary adverse event reports are vital tools for ensuring safety after drugs go to market, the FDA’s active surveillance approach through the Sentinel System is much more powerful. Saama gives pharma the same real-world data analytics capabilities in order to be more proactive about safety.
- Identify outcomes associated with any drug in the marketplace
- Understand the safety profiles of competitive products
- Explore potential causal relationships between drug/outcome pairs
- Respond rapidly and comprehensively to regulatory requests and potential findings
Active Safety Analytics for Pharma (ASAP)
Use real-world data (RWD)—healthcare claims and electronic medical records (EMR)—to find associations between any drug in the marketplace and patient outcomes. Just like the FDA’s Sentinel Initiative, ASAP leverages an advanced statistical (TreeSCan) methodology to unlock specific safety signals from billions of records in the health profiles of millions of patients.
Get Started Today
To arrange a demo and learn more about how you can set up ASAP as a secure subscription service in the cloud, contact us!